NCT00362336View on ClinicalTrials.gov

Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV

PHASE3CompletedINTERVENTIONAL
Enrollment

622

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

May 31, 2008

Study Completion Date

August 31, 2009

Conditions
Hepatitis BPolioDiphtheriaPertussisHaemophilus Influenzae Type b
Interventions
BIOLOGICAL

DTaP-IPV-HB-PRP~T

0.5 mL, Intramuscular (IM)

BIOLOGICAL

CombAct-HIB®

0.5 mL, IM

BIOLOGICAL

Engerix B® Pediatric

0.5 mL, IM

Trial Locations (2)

2013

Soweto

Unknown

Bertsham

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00362336 - Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV | Biotech Hunter | Biotech Hunter